Convulsive disorders of diverse aetiology occur frequently in the neonatal period. Symptomatic treatment often involves termination of acute seizures with intravenous diazepam and subsequent maintenance therapy with phenobarbitone (Holden and Freeman, 1975) , after excluding disorders requiring specific therapy, such as hypoglycaemia. The rate of elimination of phenobarbitone is slow especially in newborn infants in whom the mean plasma half-life is about 200 hours (Wallin et al., 1974; Boreus et al., 1975) . Therefore, initiation of phenobarbitone maintenance therapy without a loading dose implies a substantial delay before achievement of steady-state plasma concentrations (Wallin et al., 1974; Rosen and Pippenger, 1975) .
Nonetheless, the potential central nervous system depressant effects of such a loading dose of the Received 18 June 1976 barbiturate have not been evaluated in the newborn, and may be detrimental in certain already depressed infants.
In this study a group of infants who had failed to respond to the usual therapy, which frequently included the use of phenobarbitone, were treated with phenytoin (DPH). This agent is of proven efficacy in the prevention of seizures both in children and adults (Buchthal et al., 1960; Svensmark and Buchthal, 1964) , and is devoid of significant depressant side effects (Toman, 1970) . There is also evidence that DPH is useful in the treatment of acute repetitive seizures in adults when the maintenance dose is preceded by an appropriate intravenous loading dose (Wallis et al., 1968) . Reports of toxicity relating to phenytoin in the newborn (Yaffe and Juchau, 1974) are not well documented. Degeneration of Purkinje cells in the cerebellum has been reported in patients receiving phenytoin, but this appears to relate to sustained toxic plasma concentrations and may therefore be avoidable and/or reversible (Valsamis and Mancall, 1973) .
There are few published data regarding the developmental sequence of mixed-function oxidative metabolism of drugs in the neonate. Drugs eliminated via this pathway, such as theophylline, are now being used for extended periods in the newborn. This paper describes age-related changes in the disposition of DPH in newborn and young infants.
Patients and methods
Clinical. 30 infants were studied and clinical details are given in Table 1 . 2 infants were born to epileptic mothers treated daily with DPH 300 mg plus phenobarbitone throughout pregnancy. Neither infant was breast fed. Signed, informed consent was obtained, and heparinized blood (about 100 I-L) was obtained from the infants by heel puncture every 12 hours for 3 days. All other infants were being treated with DPH for convulsive disorders. (Capper and Smith, 1960) . Patients E, F, M, 0, P received the maintenance dose intravenously for 7-10 days. 'Trough' plasma DPH concentrations were measured daily immediately before a dose was given throughout the study period. The plasma concentration of DPH was considered to be at steady-state, Cp08, only after at least 7 days of maintenance therapy. For the analysis of Cp00 data (Table 3) Standard solutions of DPH, initially in ethanol, then diluted in buffer, were prepared. An antiserum dilution of 1: 500 was used, and plasma samples were diluted 1:100 in sodium phosphate buffer, 0 1 mol/l, ph 6 7, before assay. A similar dilution of control human plasma (adult) was added to standards. A standard curve performed in the presence of neonatal plasma did not differ significantly. After an incubation period of 2 5 hours on ice, incubation volume 0 7 ml, separation of bound and free DPH was achieved with use of 0 5 ml dextran-coated charcoal, 0 5 %. After centrifugation at 4°C, the supernatant was admixed with Bray's solution, and radioactivity was determined in a Beckman LS-1 50 scintillation counter with external quench correction. RIA data were analysed using a regression of logit B/Bo versus log10 standard concentration with a PDP-8 computer. Lederle quality control sera* were included in each assay at two dilutions corresponding to 5 and 20 ng DPH. 30 plasma samples containing DPH over the concentration range 0-35 mg/l (0-140 ,umol/l) were analysed by RIA and by gas-liquid chromatography (Sherwin et al., 1973) (Fig. 2) .
Plasma protein binding of DPH. Plasma protein binding ofDPH was measured using an ultra filtration technique (Amicon CF50 Cones, Boston, Mass.) after incubation of plasma samples, 2-0 ml, for one hour at 37°C under 5% carbon dioxide in air with 14C-enriched DPH (New England Nuclear, Boston, Mass.) at a total DPH concentration of 15 mg/l (60 ,mol/l). Plasma samples were obtained from (Table 2B ) aged 2-18 days also showed prolonged and highly variable half lives (75 4 ±64 5 h). These 4 infants (and patient K) were the only patients in the entire study who did not receive phenobarbitone concurrently. The greatly prolonged half-life in patient 0 may also have related to severe liver disease in addition to prematurity. Since the study period in these infants with convulsive disorders was restricted to 24 hours, the numerical values assigned to the longer half-lives must be considered approximations. Fig. 4 were treated with the (Ehrenbo et al., 1971 ) and displacement of the hydantoin by bilirubin (Rane et al., 1971) and fatty acids (Fredholm et al., 1975) have been reported. Since the plasma concentration of unbound drug is likely to correlate better than total drug with pharmacological effect (Booker and Darcey, 1973) , it is important to ascertain protein binding throughout childhood in order to interpret the significance of observed total plasma DPH concentrations. In fact, diminished protein binding could contribute to observed low steady-state concentrations in infants more than 2 weeks of age (Table 3) . Unfortunately, sample volume considerations prevented detailed study of binding in the plasma of infants less than 3 months old (except for cord plasma), but the data in Table 4 show that, at a total DPH concentration of 15 mg/l (60 ,umol/l) the impaired binding seen neonatally had approached adult values by 3 months of age. The binding of DPH throughout childhood differed slightly from adults. These differences are of borderline statistical and of no clinical significance.
Discussion
DPH elimination in man occurs largely via the hepatic microsomal mixed function oxidase reaction with subsequent glucuronidation and excretion of the hydroxylated derivatives, mainly HPPH (Chang and Glazko, 1972) . In adults the oxidation of DPH exhibits saturability at high plasma concentrations (Arnold and Gerber, 1970) . Horning et al. (1975) have found HPPH (5-p-OH phenyl, phenylhydantoin) and its glucuronide, as well as the dihydrodiol derivative, in the urine of infants who had been exposed to DPH transplacentally or after birth. Identical metabolites have been found in adult urine. Indeed, the relative proportions of DPH, HPPH, and conjugated HPPH in urine from neonates who had acquired DPH (and perhaps, metabolites) transplacentally resemble those seen in urine from adult man (Reynolds and Mirkin, 1973; Rane, 1974) . Pharmacokinetic investigations of DPH in infants have been reported by Mirkin (1971, 7 newborns, transplacental acquisition), Rane et al. (1974, 7 newborns, transplacental acquisition), Baughman and Randinitis (1970, 1 newborn, transplacental acquisition), and Jalling et al. (1970, steady- state plasma concentrations in 6 infants, 5 of whom were more than 3 weeks old). The interpretation of events in each study and the method of data analysis have influenced conclusions. Mirkin (1971) , though noting that elimination was 'very slow on postpartum days 1 and 2, and increased markedly on postpartum day 3', pooled data and derived an average plasma halflife of about 60 hours. Rane et al. (1974) thought the early slow phase of elimination reflected saturation kinetics; analysis of the subsequent first order decay curves omitted the events of the first few days and yielded plasma half-lives (6 6-34 h) similar to adult values. Jalling et al. (1970) observed surprisingly low steady-state plasma concentrations of DPH after multiple intramuscular or oral doses in older infants. The data presented here are consistent with each set of observations.
The single intravenous dose studies suggest that the low steady-state plasma concentrations observed after 2 or 3 weeks of age reflect primarily the shorter half-life in young infants relative to the adult. The data probably reflect maturation of drug oxidative activity . Indeed, when the halflives derived for the term infants reported here are combined with estimates calculated from reported data (Baughman and Randinitis, 1970; Jalling et al., 1970; Mirkin 1971; Rane et al., 1974) , mean DPH plasma half-lives of about 80, 15, and 6 hours are found for the age groups 0-2, 3-14, and 15-150 days, respectively (Fig. 6 ). Large intersubject variability is seen during the first few postnatal days with half-lives ranging from <10 to >100 hours; the variability diminishes with age. Since many of the infants in these series also received phenobarbitone, the influence of the latter on the developmental pattern cannot be excluded. None- (Vest and Streiff, 1959) , diazepam (Morselli et al., 1973) , phenobarbitone (Wallin et al., 1974; Boreus et al., 1975) , and amylobarbitone (Draffan et al., 1976) .
The observed clearance of DPH per unit body weight in young infants beyond the neonatal period is considerably higher than that reported in adults (Glazko et al., 1969) . This phenomenon has been observed not only with DPH (Svensmark and Buchthal, 1964) but also with phenobarbitone (Heinze and Kampffmeyer, 1971) , theophylline , phenylbutazone, and antipyrine (Alvares et al., 1975) .
Clinical trials based on reported data, and comparing the efficacy and toxicity of available anticonvulsants are needed to determine optimal therapy for the newborn and young infant. In the absence of pharmacodynamic data in this 'age group, an appropriate therapeutic plasma DPH concentration must be selected. Data reported in adults and older children suggest that plasma concentrations of 10-20 mg/l (40-80 ,tmol/l) are effective (Buchthal et al., 1960) . The impaired protein binding seen with cord plasma may persist through the first weeks of life, as has been shown for bilirubin (Kapitulnik et al., 1975) . Such impaired binding in the newborn would indicate a higher concentration of unbound DPH at any given total plasma concentration. A therapeutic concentration range of 6-14 mg/l (mean 10 mg/I, total drug; 24-56 tLmol/l, mean 40) may therefore be more appropriate in the immediate neonatal period. An intravenous loading dose of 8 mg/kg phenytoin sodium would be expected to achieve rapidly a mean plasma DPH concentration of 10 mg/I (40 ,tmol/l) in all age groups studied. No toxicity has been noted using a 15-minute infusion of 12 mg/kg which produced a mean C°p of 15 mg/l (60,mol/l).
The selection of a maintenance dose rate is difficult because of the rapidly changing and variable elimination of DPH after birth. Certainly the maintenance dose rate used in this study, 8 mg/kg per 24 h, resulted in potentially toxic accumulation in some infants during the first postnatal week (Fig.   3) ; other infants of the same age showed subtherapeutic concentrations (Fig. 4) (Arnold and Gerber, 1970) . Such zero-order kinetics, though not evident in this study (Fig. 1) , cannot be confidently excluded with the doses and methodology used. When such low plasma concentrations are documented in infants with inadequate seizure control, the dosage should be increased with monitoring of plasma concentration of DPH. 
